BKA
UTHR icon

Brick & Kyle Associates’s United Therapeutics UTHR Stock Holding History

Brick & Kyle Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-75
Closed -$13K – 463
2015
Q1 		$13K Sell
75
-95
-56% -$14.5K 0.01% 346
2014
Q4 		$22K Buy
+170
New +$21.9K 0.02% 260

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Brick & Kyle Associates's UTHR Position: Q2 2015 in Review

Brick & Kyle Associates sold out of United Therapeutics (UTHR) in Q2 2015, closing a stake of 75 shares — an estimated $13K sold.

Brick & Kyle Associates first reported a position in UTHR in Q4 2014 and held it in 2 quarters. The position peaked at $22K in Q4 2014. 383 funds tracked by Wall St. Rank hold UTHR as of Q2 2015.

  • Brick & Kyle Associates reported no remaining United Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Brick & Kyle Associates sold 75 United Therapeutics shares in Q2 2015, an estimated $13K.
  • Brick & Kyle Associates first reported a position in United Therapeutics in Q4 2014 and held it in 2 quarters.
  • Brick & Kyle Associates's United Therapeutics position peaked at $22K in Q4 2014.
  • 383 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2015.

Based on Brick & Kyle Associates's 13F filing for Q2 2015, filed 14 Jul 2015.